Viscosupplementation is the term used for decompressing a spinal joint. As a result of this, the pressure on surrounding structures decreases, allowing for easier movement within the joint. Another key factor aiding growth of the said market is rapidly rising geriatric population. Elderly people are most vulnerable to orthopedic diseases due to weakened bones. As per the Eurostat, in 2020, over 20.6% of the EU population was aged 65 years and above. Thus, elderly people are more likely to suffer from orthopedic diseases such as osteoarthritis, osteoporosis, and more. Hence, such factors can augment growth of the Europe viscosupplementation market. Recently, in December 2019, Fidia Pharma USA Inc. launched TRILURON, a hyaluronic acid (HA)-based intra-articular viscosupplement indicated for the treatment of pain in osteoarthritis of the knee.
Viscosupplementation is not a cure-all. It is most effective when used after other treatments have failed. In fact, to date, there are still no studies comparing osteoarthritis sufferers with those who undergo Viscosupplementation before, during, and after therapy. However, it has been shown to be much safer and more effective than many of the other osteoarthritis injections and medications currently on the market.
Read More: https://bit.ly/3z2RSEn
